Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + venetoclax
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
Cytarabine + venetoclax is a combination regimen used primarily for the treatment of acute myeloid leukemia (AML), especially in adults who are newly diagnosed and ineligible for intensive chemotherapy. Cytarabine is an antimetabolite chemotherapeutic agent that inhibits DNA synthesis by acting as a cytosine analog, leading to cell death in rapidly dividing cells. Venetoclax is a selective small molecule inhibitor of B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein; by inhibiting BCL-2, it promotes apoptosis in malignant hematopoietic cells. The combination has demonstrated improved response rates and overall survival compared to low-dose cytarabine alone in clinical trials such as VIALE-C[1][2][5]. This regimen is approved for use in AML patients who cannot tolerate intensive induction therapy.
- Other names
- cytarabine and venetoclaxlow-dose cytarabine plus venetoclaxLDAC + venetoclax
02
Targets
BCL-2 (BCL-2 family)DNA
Beyond the preview
Go deeper on cytarabine + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + venetoclax.